Effects of Tamoxifen and Other SERMs in the Endometrium and Follow-Up of Patients

Hormone therapy remains an integral part of the treatment of hormone receptor-positive breast cancers. Tamoxifen, a selective estrogen receptor modulator, is the most common hormonal agent used in this scenario. Selective estrogen receptor modulators (SERMs) are competitive inhibitors of estrogen receptors which have an estrogen agonist and antagonist effect depending on target tissues. The antiestrogenic effect is by blocking the binding of estrogen to estrogen receptors. Access this chapter Tax calculation will be finalised at checkout Purchases are for personal use only Similar content being viewed by others

Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of estrogen receptor-positive breast cancer: ATLAS, a randomized trial. Lancet 2013;381:805–16. Fisher B, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 1998;90:1371–88. Early Breast Cancer Trialists Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant Tamoxifen: patient-level meta-analysis of randomized trials. Lancet. 2011;378:771–84. Martel C, et al. Prevention of bone loss by EM-800 and raloxifene in the ovariectomized rat. J Steroid Biochem Mol Biol. 2000;74:45–56. Willson TM, et al. 3-[4-(1, 2-Diphenylbut-1-enyl) phenyl] acrylic acid: a non-steroidal estrogen with functional selectivity for bone over uterus in rats. J Med Chem. 1994;37:1550–2. Sismond P, Biglia N, Volpi E, Giai M, de Grandis T. Tamoxifen and endometrial cancer. Ann N Y Acad Sci. 1994;734:310–21. Bissett D, Davis JA, George WD. Gynaecological monitoring during tamoxifen therapy. Lancet. 1994;344:1244. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen treated breast cancer patients. National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 1994;86:527–37. Update of the national surgical adjuvant breast and bowel project study of tamoxifen and raloxifene (STAR) P-2 Trial: preventing breast cancer p. 681, 686, 689. Lahti E, Blanco G, Kauppila A, Apala-Sarkkinen M, Tsinan PJ, Laatikainen T. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol. 1993;81:660–4. Neven P, De Muylder X, Van Belle Y, Venderick G, De Muylder E. Tamoxifen and the uterus and endometrium. Lancet. 1989;8(1):375. Cheng WF, Lin HH, Torng PL, Huang SC. Comparison of endometrial changes among symptomatic tamoxifen treated and non treated premenopausal and postmenopausal breast cancer patients. Gynecol Oncol. 1997;66:233–7. Ismail SM. Pathology of endometrium treated with tamoxifen. J Clin Pathol. 1994;47:827–33. Tergas AI, Buell-Gutbrod R, Gwin K, Kocherginsky M, Temkin SM, Fefferman A, Lengyel E, Yamada SD. Clinico-pathologic comparison of type II endometrial cancers based of tamoxifen exposure. Gynecol Oncol. 2012;127:316–20. Biron-Shental T, Tepper R, Fishman A, Shapira J, Cohen I. Recurrent endometrial polyps in postmenopausal breast cancer patients on tamoxifen. Gynecol Oncol. 2003;90:382–6. Deligdisch L, Kalir N, Cohen CJ, de Latour M, Le Bouedec G, Penault-Llorca F. Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer. Gynecol Oncol. 2000;78:181–6. Ashraf M, Biswas J, Majumdar S, Nayak S, Alam N, Mukherjee KK, Gupta S. Tamoxifen use in Indian women-adverse effects revisited Asian Pacific. J Cancer Prev. 2009;10:609–12. Barakat RR, Gilewski TA, Almadrones L, et al. Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: a prospective study using office endometrial biopsy. J Clin Oncol. 2000;18:3459–63. Gerber B, Krause A, Muller H, et al. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound. J Clin Oncol. 2000;18:3464–70. Kedar RP, Bourne TH, Powles TJ, Collins WP, Ashley SE, Cosgrove DO, Campbell S. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet. 1994;343(8909):1318–21. Cohen I, Rosen DJ, Tepper R, Cordoba M, Shapira Y, Altaras MM, et al. Ultrasonographic evaluation of the endometrium and correlation with endometrial sampling in postmenopausal patients treated with tamoxifen. J Ultrasound Med. 1993;12:275–80. Markovitch O, Tepper R, Aviram R, Fishman A, Shapira J, Cohen I. The value of sonohysterography in the prediction of endometrial pathology in asymptomatic postmenopausal breast cancer tamoxifen treated patients. Gynecol Oncol. 2004;94:754–9. Author information Authors and Affiliations Corresponding author Editor information Editors and Affiliations Rights and permissions Copyright information © 2015 Springer India About this chapter Cite this chapter Suchetha, S. (2015). Effects of Tamoxifen and Other SERMs in the Endometrium and Follow-Up of Patients. In: Rajaram, S., K, C., Maheshwari, A. (eds) Uterine Cancer. Springer, New Delhi. https://doi.org/10.1007/978-81-322-1892-0_41 Download citation DOI: https://doi.org/10.1007/978-81-322-1892-0_41 Publisher Name: Springer, New Delhi Print ISBN: 978-81-322-1891-3 Online ISBN: 978-81-322-1892-0 eBook Packages: MedicineMedicine (R0)

- Endometrial Cancer - Breast Cancer Mortality - Selective Estrogen Receptor Modulator - Endometrial Thickness - Endometrial Hyperplasia These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.